Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. (OTCMKTS: DMTTF) held their respective annual general and special shareholders meetings on October 12. They announced that voting results favored the arrangement plan for the latter’s acquisition by the former.
The TSX Venture Exchange conditionally approved the arrangement. Subject to the approval of BC’s Supreme Court and other customary closing conditions, the arrangement’s effective date would take place on or around October 23, 2023. Read more HERE.
FDA Issues Warning Over Ketamine Misuse, DEA Extends Telemedicine Flexibilities
The FDA issued an alert on the dangers of self-treating psychiatric disorders with unapproved compounded versions of ketamine and ketamine-based drugs whether modified or tailored for specific patient needs.
Meanwhile, the DEA announced on October 6 that, for a second time, it is extending pandemic-established temporary rules deviating from the Ryan Haight Act conditions and effectively allowing telehealth prescriptions of controlled medications through December 31, 2024. More on both news HERE.
Gov. Gavin Newsom Vetoes California Psychedelics Bill, Leaves Door Open For Next Year
California Gov. Gavin Newsom (D) vetoed a bill on Saturday that would have decriminalized the possession and personal use of certain hallucinogens, including psychedelic mushrooms. The bill would not have legalized the sale of these substances, but rather sought to ensure that individuals were not arrested or prosecuted for having small amounts of plant-based hallucinogens.
Newsom said in a statement that more needs to be done before California decriminalizes hallucinogens. More HERE.